BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 8254663)

  • 1. Synergism between Tat and VP16 in trans-activation of HIV-1 LTR.
    Ghosh S; Selby MJ; Peterlin BM
    J Mol Biol; 1993 Dec; 234(3):610-9. PubMed ID: 8254663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for functional interaction between the HIV-1 Tat transactivator and the TATA box binding protein in vivo.
    Veschambre P; Simard P; Jalinot P
    J Mol Biol; 1995 Jul; 250(2):169-80. PubMed ID: 7608968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 tat transcriptional activity is regulated by acetylation.
    Kiernan RE; Vanhulle C; Schiltz L; Adam E; Xiao H; Maudoux F; Calomme C; Burny A; Nakatani Y; Jeang KT; Benkirane M; Van Lint C
    EMBO J; 1999 Nov; 18(21):6106-18. PubMed ID: 10545121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the human homolog of the yeast transcription factor SPT5 in HIV-1 Tat-activation.
    Wu-Baer F; Lane WS; Gaynor RB
    J Mol Biol; 1998 Mar; 277(2):179-97. PubMed ID: 9514752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic HIV-1 Tat can dissociate HeLa nuclear protein-TAR RNA complexes in vitro: a novel Tat-nuclear protein interaction.
    Jeyapaul J; Seshamma T; Khan SA
    Oncogene; 1991 Sep; 6(9):1507-13. PubMed ID: 1923518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional similarities between HIV-1 Tat and DNA sequence-specific transcriptional activators.
    Madore SJ; Cullen BR
    Virology; 1995 Feb; 206(2):1150-4. PubMed ID: 7856090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tat-dependent repression of human immunodeficiency virus type 1 long terminal repeat promoter activity by fusion of cellular transcription factors.
    Zhao C; Chen Y; Park J; Kim JB; Tang H
    Biochem Biophys Res Commun; 2004 Sep; 322(2):614-22. PubMed ID: 15325274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional activation by DNA-binding derivatives of HSV-1 VP16 that lack the carboxyl-terminal acidic activation domain.
    Popova B; Bilan P; Xiao P; Faught M; Capone JP
    Virology; 1995 May; 209(1):19-28. PubMed ID: 7747469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression.
    Modesti N; Garcia J; Debouck C; Peterlin M; Gaynor R
    New Biol; 1991 Aug; 3(8):759-68. PubMed ID: 1931822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twenty-one base pair repeat elements influence the ability of a Gal4-Tax fusion protein to transactivate the HTLV-I long terminal repeat.
    Connor LM; Oxman MN; Brady JN; Marriott SJ
    Virology; 1993 Aug; 195(2):569-77. PubMed ID: 8337832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 regulatory protein tat induces RNA binding proteins in central nervous system cells that associate with the viral trans-acting-response regulatory motif.
    Kundu M; Ansari SA; Chepenik LG; Pomerantz RJ; Khalili K; Rappaport J; Amini S
    J Hum Virol; 1999; 2(2):72-80. PubMed ID: 10225209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence.
    Tiley LS; Madore SJ; Malim MH; Cullen BR
    Genes Dev; 1992 Nov; 6(11):2077-87. PubMed ID: 1427073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein.
    Southgate C; Zapp ML; Green MR
    Nature; 1990 Jun; 345(6276):640-2. PubMed ID: 2190099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The human immunodeficiency virus type 1 Vpr transactivator: cooperation with promoter-bound activator domains and binding to TFIIB.
    Agostini I; Navarro JM; Rey F; Bouhamdan M; Spire B; Vigne R; Sire J
    J Mol Biol; 1996 Sep; 261(5):599-606. PubMed ID: 8800208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basal components of the transcription apparatus (RNA polymerase II, TATA-binding protein) contain activation domains: is the repetitive C-terminal domain (CTD) of RNA polymerase II a "portable enhancer domain"?
    Seipel K; Georgiev O; Gerber HP; Schaffner W
    Mol Reprod Dev; 1994 Oct; 39(2):215-25. PubMed ID: 7826625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression.
    Lisziewicz J; Rappaport J; Dhar R
    New Biol; 1991 Jan; 3(1):82-9. PubMed ID: 2039768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tackling Tat.
    Karn J
    J Mol Biol; 1999 Oct; 293(2):235-54. PubMed ID: 10550206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA.
    Rana TM; Jeang KT
    Arch Biochem Biophys; 1999 May; 365(2):175-85. PubMed ID: 10328810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exon2 of HIV-2 Tat contributes to transactivation of the HIV-2 LTR by increasing binding affinity to HIV-2 TAR RNA.
    Rhim H; Rice AP
    Nucleic Acids Res; 1994 Oct; 22(21):4405-13. PubMed ID: 7971271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an N-terminal transcriptional activation domain within Brn3b/POU4f2.
    Martin SE; Mu X; Klein WH
    Differentiation; 2005 Feb; 73(1):18-27. PubMed ID: 15733064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.